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Background: Acinetobacter baumannii is a notorious opportunistic pathogen mainly associated with hospital-
acquired infections. Studies on the clonal relatedness of isolates could lay the foundation for effective infection
control. A snapshot study was performed to investigate the clonal relatedness of A. baumannii clinical isolates in
our local settings.
Results: Among 82 non-repetitive Acinetobacter spp. clinical isolates that were recovered during a period of four
days in 13 hospitals in Sichuan, Southwest China, 67 isolates were identified as A. baumannii. Half of the 67 A.
baumannii isolates were non-susceptible to carbapenems. blaOXA-23 was the only acquired carbapenemase gene
detected, present in 40 isolates including five carbapenem-susceptible ones. The isolates belonged to 62 pulsotypes
determined by PFGE and 31 sequence types (ST) by multi-locus sequence typing. Forty-three isolates belonged to
the globally-disseminated clonal complex 92, among which ST75, ST92 and ST208 were the most common
sequence types.
Conclusions: Clinical isolates of A. baumannii were diverse in clonality in this snapshot study. However, most of the
isolates belonged to the globally-distributed clonal complex CC92. ST75, ST92 and ST208 were the most common
types in our region. In particular, ST208 might be an emerging lineage carrying blaOXA-23.
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Acinetobacter baumannii is one of the common bacterial
species responsible for hospital-acquired infections (HAIs)
[1]. The prevalence of multi-drug resistant (MDR) A.
baumannii in hospitals has been increasing worldwide [2],
representing a serious challenge for clinical management
and public health. Investigation on the clonal relatedness of
A. baumannii in local settings could generate useful data to
understand the local epidemiology of this opportunistic
pathogen and therefore lay a foundation for an effective in-
fection control program. Previous studies have focused on
the clonal relatedness of A. baumannii but the vast major-
ity of these studies were retrospective and used a collection
of isolates either from outbreaks or with little information
on their representativeness. For hospitals in Sichuan,* Correspondence: zongzhiy@scu.edu.cn
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reproduction in any medium, provided the orSouthwest China, A. baumannii was a huge problem as it was
the most common bacterial species associated with HAIs and
accounted for 17.3% of putative pathogens causing HAIs in a
point prevalence survey [3]. Outbreaks due to A. baumannii
had also been reported in our hospitals [4]. A snapshot study
was therefore performed to investigate the clonal relatedness
of A. baumannii clinical isolates in our local settings.
Results and discussion
Among 82 non-repetitive isolates that were recovered from
clinical specimens from June 22 to June 25, 2011 in 13 hos-
pitals in Sichuan and were putatively identified as A.
baumannii by automated microbiology systems, 67 isolates
were validated to be A. baumannii. The vast majority (61/
67, 91%) of the A. baumannii isolates were recovered from
sputa or respiratory tract secretions. The remaining six iso-
lates were from ascites, cerebrospinal fluid, drainage,
pleural fluid or wound secretions. As for the clinical signifi-
cance, A. baumannii isolates were considered as either col-
onizers (55.2%) or pathogens (44.8%) causing clinical
infections.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were non-susceptible to carbapenems (34 non-susceptible
to both imipenem and meropenem and 1 non-susceptible
to meropenem only), which was in consistence with the
53% carbapenem resistance rate of A. baumannii in the
2010 report of Chinese Ministry of Health National Anti-
microbial Resistance Investigation Net (MOHNARIN) [5].
Many isolates were non-susceptible to sulbactam (35/67,
52.2%), ceftazidime (39/67, 58.2%), ciprofloxacin (43/67,
64.2%) or cotrimoxazole (47/67, 70.1%) while all isolates
were susceptible to polymyxin and rifampicin and only one
isolate was non-susceptible to minocycline.
blaOXA-23 was the only acquired carbapenemase gene
that was detected. Interestingly, it was present in 35/35
carbapenem-non-susceptible and 5/32 carbapenem-
susceptible isolates. blaOXA-23 has been the most com-
mon carbapenemase gene in China, as a previous study
reported that 322 out of 342 (94.2%) imipenem-non-
susceptible A. baumannii isolates collected from 16
Chinese cities had blaOXA-23 [6]. Although blaOXA-23 en-
codes a carbapenemase, this gene has also been detected
in carbapenem-susceptible isolates before [7].
The isolates were assigned to 62 pulsotypes deter-
mined by pulsed-field gel electrophoresis (PFGE),
suggesting quite diverse clonal relatedness (Figure 1). A
total of 31 sequence types (STs), including 19 new STs,
were assigned for the isolates using the multi-locus se-
quence typing (MLST) with the pubmlst scheme (Table 1
and Figure 2). As the gdhB gene sequence was not
obtained from isolate d34 despite repeated attempts
using various primer pairs, the ST could not be assigned
for this isolate. Of note, two isolates of the same
pulsotypes were assigned to different STs, ST118 and
ST218. However, ST118 and ST218 were found to be
single locus variants to each other. This was in consist-
ence with a previous study [8] reporting that isolates be-
longing to the same puslotype were not always of the
same STs.
ST75, ST92 and ST208 were the most common STs in
our local settings as each of them were found in three to
five hospitals scattered in different regions of the prov-
ince. ST92 and ST75 were prevalent in West China Hos-
pital in a study carried out in 2006 [7] and were also the
most common STs in China in 2005 [9]. In contrast,
ST208 had not been identified in China before, although
it was found in five hospitals in this study. All our
ST208 isolates except one carried blaOXA-23. ST208 has
recently become one of the two most common STs of
carbapenem-non-susceptible isolates in the United
States [10], suggesting that ST208 might be an emerging
lineage carrying carbapenem resistance determinants.
ST92, a globally-distributed type, and its 103 closely-
related STs including ST75, ST118, ST136, ST138,
ST191, ST208, ST218, ST368, ST381 and ST433detected in this study comprised the clonal complex 92
(CC92, Figure 2), corresponding to the pan-European
clone II (EUII; the international clone 2) [11]. Although
diverse types were detected, 43 isolates belonged to the
CC92. Among the 104 STs of CC92, 35 STs were differ-
ent from ST92 only in the gpi locus. Isolate information
was available for 22 of these 35 STs, 14 of which have
only been found in the East or Southeast Asia at present.
The 20 non-CC92 STs identified in the present study
were either singletons (n = 12) or of a CC that was not a
common international clone (Table 1).
A total of 575 STs were assigned in the Acinetobacter
MLST database (http://pubmlst.org/abaumannii/, accessed
by May 19, 2013), among which isolates identified as A.
baumannii belonged to 545 STs. The 305-bp gpi locus of
A. baumannii appeared to diverge much faster than other
loci, with 149 gpi allele types comparing to 45 gltA, 84 gyrB,
85 gdhB, 53 recA, 42 cpn60 and 63 rpoD. The occurrence
of a different gpi allele for every three STs deposited in the
pubmlst database raised the concern that gpi might not be
an ideal locus for typing. A previous study [8] also sug-
gested that gpi was not a good candidate for MLST analysis
due to recombination. Therefore, the diversity of A.
baumannii generated by variations in the gpi locus alone
might need validation to appreciate whether the diversity is
truly meaningful.
Isolates belonging to each of 19 new STs were assigned
to 18 STs using the Pasteur scheme (Table 1). Among
the 18 STs determined by the Pasteur scheme, 12 had
not been seen before and therefore were truly new STs.
Although 411 STs of A. baumannii had been assigned in
the pubmlst database before this study, a few new STs
were still detected in a relatively small collection,
suggesting that A. baumannii is likely to be extremely
diverse in clonal origins or is undergoing a significant
clonal expansion. Of note, the isolates with new STs
were all carbapenem-susceptible except one. blaOXA-23
was not detected in most (17/21) isolates of the novel
STs. This phenomenon was also present in this study as
all the local carbapenem-resistant isolates carrying
blaOXA-23 belonged to CC92. It has been suggested that
among carbapenem-resistant isolates some belonging to
certain clonal complexes appeared to be more successful
[12-14].
The diversity of A. baumannii isolates in our settings
could provide useful information for infection control. The
clonal diversity of A. baumannii and the fact that
carbapenem resistance could be transmitted horizontally
highlight that “horizontal” infection control measures such
as environmental cleaning and hand hygiene should be
reinforced to reduce the further spread of A. baumannii.
Person-to-person transmission of carbapenem-non-
susceptible A. baumannii carrying blaOXA-23 was indeed






















































































































































































































































































Figure 1 PFGE patterns of A. baumannii isolates. Dendrogram was generated by BioNumerics software with the unweighted pair-group
method using arithmetic averages (UPGMA). Isolate name, ST, CC and the carriage of blaOXA-23 (Y, positive; N, negative) are indicated. The ST
numbers shown after slash are assigned using the Pasteur MLST scheme.
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Table 1 Profiles of A. baumannii clinical isolates
ST1 ST profile1: CC2 Isolates
no.









17 1-12-12-11-4-10-3 17 2 WC 3, 36 1 0
75 1-3-3-2-2-11-3 92 6 DZ, MY, WC 4, 24, 26, 37, 50, 51 5 4
92 1-3-3-2-2-7-3 92 8 DY, DZ, MY, NC, WC 2, 8, 28, 34, 41, 47, 49, 56 6 6
118 1-3-3-2-2-3-3 92 2 MY 43, 44 2 2
136 1-3-3-2-2-16-3 92 1 WC 57 0 0
138 1-3-3-2-2-50-3 92 3 WC 25, 29, 61 1 1
184 36-31-59-28-4-54-4 S 1 SN 12 0 0
191 1-3-3-2-2-94-3 92 2 WC 33, 45 2 2
208 1-3-3-2-2-97-3 92 13 LS, LZ, MY, WC, YA 20 (2)4, 21, 22, 23, 27, 38, 39, 40, 46, 48, 49 9 12 12
218 1-3-3-2-2-102-3 92 2 MY 42, 44 2 2
368 1-3-3-2-2-140-3 92 2 MY, WC 24, 60 2 2
381 1-81-3-3-2-2-16-3 92 3 LE, PZ 1, 18 (2)4 3 3
427/40 1-31-12-11-4-25-3 17/216 2 WC 15, 62 2 0
428/33 21-15-2-28-1-52-4 145/33 1 WC 54 0 0
429/332 1-34-56-1-4-144-45 S/216 2 MS, WC 5, 14 0 0
430/333 1-31-49-10-1-103-4 S/S 1 WC 30 0 0
431/334 34-12-68-41-1-104-4 80/34 1 WC 55 0 0
432/34 34-12-68-41-32-104-4 80/34 1 NC 32 0 0
433/2 1-81-3-1-2-16-3 92/2 1 PZ 19 1 1
475/113 18-44-2-28-1-151-71 S/113 1 WC 35 0 0
476/341 35-50-42-49-48-157-5 S/S 1 WC 31 0 0
477/268 1-50-56-2-1-152-26 S/216 1 ZG 9 0 0
478/339 33-89-40-26-32-91-5 163/S 1 WC 13 0 0
479/331 52-39-80-5-1-161-12 S/216 1 WC 58 0 0
480/331 1-34-80-28-1-160-45 172/216 1 WC 7 0 0
481/340 1-12-67-6-50-159-6 S/243 1 WC 6 0 0
482/335 1-90-6-1-36-102-6 S/216 1 NC 17 0 0



















Table 1 Profiles of A. baumannii clinical isolates (Continued)
484/337 1-91-130-1-36-110-72 S/S 1 DZ 16 0 0
485/338 33-12-59-11-32-158-5 334/S 1 DY 10 0 0
503/336 1-62-80-28-35-164-45 S/216 1 LZ 11 0 0
ND/203 1-34-ND-28-1-165-45 /216 1 WC 53 1 0
1ND, not determined. For new STs (ST427 and above) and the undetermined ST by the pubmlst scheme, STs determined using the Pasteur MLST scheme are shown after the slash “/” with new STs being underlined.
2CC, clonal complex. S, singleton. CCs for STs determined using the Pasteur MLST scheme are shown after the slash “/” . The members of CCs for STs determined using the pubmlst scheme in Table 1 other than CC92
are listed as below. CC17 (n = 6): ST17, ST373, ST427, ST528, ST530, ST554; CC80 (n = 4): ST80, ST360, ST431, ST432; CC145 (n = 11): ST85, ST86, ST144, ST145, ST153, ST158, ST376, ST401, ST428, ST552, ST553; CC163
(n = 8): ST163, ST164, ST165, ST166, ST167, ST458, ST478, ST574; CC172 (n = 3): ST172, ST412, ST480; CC334 (n = 2): ST334, ST485.
3Hospital: DY, Deyang People’s Hospital, Deyang city; DZ, Dazhou Central Hospital, Dazhou city; LE, Leshan People’s Hospital, Leshan city; LS, The First Hospital of Liangshan Prefecture, Xichang city; LZ, Affiliated
Hospital of Luzhou Medical College, Luzhou city; MS, Meishan People’s Hospital, Meishan City; MY, Mianyang Central Hospital, Mianyang city; NC, Affiliated Hospital of North Sichuan Medical College, Nanchong city; PZ,
Panzhihua Central Hospital, Panzhihua city; SN, Suining Central Hospital, Suining city; WC, West China Hospital of Sichuan University, Chengdu city; YA, Yaan People’s Hospital,Yaan city; ZG, The First Municipal Hospital
of Zigong, Zigong city.



















Figure 2 STs seen in this study and the CC92. Panel A. The relatedness of the STs seen in this study. Panel B. The clonal complex 92 (CC92).
eBURST was performed using 6 as the minimum identical loci for the definition of CC and 3 as the minimum single locus variants. The countries
of isolation are shown according to the pubmlst database. The STs found in this study are in bold. NA, information not available. ST208 is
predicted as the founder ST for CC92 by eBURST.
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http://www.biomedcentral.com/1471-2180/13/234isolates recovered from different patients belonged to the
same pulsotype (Table 1 and Figure 1). This suggests that ef-
fective infection control measures might need to include
rapid identification of blaOXA-23 by molecular methods and
also justifies contact precautions for patients with
carbapenem-resistant isolates.Conclusions
This study provided a snapshot of A. baumannii popula-
tion in clinical samples in our local settings. Significantly
diverse clonal origins were identified but most isolates
belonged to the globally-distributed CC92. Among
CC92, ST75, ST92 and ST208 were the most common
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ing blaOXA-23 suggests that ST208 appears to be an
emerging lineage mediating the spread of carbapenem
resistance. The diversity of A. baumannii suggested that
the current MLST scheme might need to be further opti-
mized and in particular the gpi gene might not be an
ideal target for Acinetobacter MLST.Methods
Strains
The study included all non-repetitive isolates (n = 82)
that were recovered from clinical specimens from June
22 to June 25, 2011 in 13 hospitals in Sichuan, southwest
China and were putatively identified as A. baumannii or
belonging to the Acinetobacter calcoaceticus-baumannii
complex using the Vitek II, MicroScan and Phoenix au-
tomated systems. The clinical samples were taken as part
of standard patient care and therefore no ethical ap-
proval was applied for their use. The 13 hospitals are all
tertiary with 19,051 beds in total (ranged from 800 to
4,300) including 3 university hospitals and 10 municipal
ones. For each patient, only one isolate was collected.
Genomic species identification was established by par-
tially sequencing the recA gene as described previously
[15].In vitro susceptibility test
MICs of meropenem, imipenem, ceftazidime, sulbactam,
minocycline, polymyxin, ciprofloxacin, rifampicin and
cotrimoxazole against A. baumannii isolates were deter-
mined using the agar dilution method following the recom-
mendations of the Clinical and Laboratory Standards
Institute (CLSI) [16]. MICs were interpreted according to
the breakpoints established by CLSI [16], except for
sulbactam and rifampicin, for which breakpoints from the
French Society for Microbiology were used (for sulbactam,
≤8 mg/L for susceptible; for rifampicin, ≤8 μg/ml for sus-
ceptible and >16 mg/L for resistant) [17]. Resistance to
imipenem or meropenem was defined as carbapenem
resistance.Detection of carbapenemase-encoding genes
Genes encoding Class A carbapenemases (blaGES and
blaKPC), Class B metallo-β-lactamases (blaIMP, blaVIM,
blaSPM, blaGIM, blaSIM and blaNDM) or Class D OXA-
type carbapenemases (blaOXA-51, blaOXA-23, blaOXA-24,
blaOXA-58 and blaOXA-143) were screened as described
previously [18-22]. Purified amplicons were sequenced
in both directions using an ABI 3730 DNA analyzer
(Applied Biosystems, Warrington, United Kingdom).
Similarity searches were carried out using BLAST pro-
grams (http://www.ncbi.nlm.nih.gov/BLAST/).Strain typing
PFGE was employed to determine clonal relatedness of
the isolates and was performed as described previously
[12]. PFGE band patterns were analyzed using the
BioNumerics software, version 6.6.4.0 (Applied Maths,
St-Martens-Latem, Belgium). Pulsotypes were defined as
isolates with PFGE band patterns of 80% similarity or
above [23].
All A. baumannii isolates were subjected to MLST
targeting seven housekeeping genes, gltA, gyrB, gdhB, recA,
cpn60, gpi and rpoD [24]. As primers used previously were
unable to amplify the gdhB and gpi alleles for some isolates
[9,24,25], new primers were therefore designed for gdhB
(gdhBxF1: ATTGGTTGCTGCCGAATAGT; gdhBxR1: TA
TGGGGGCCAGATAATCAA) and gpi (gpi-F2: AAA
ATCCATGCTGGGCAATA; gpi-R2: CCGAGTAATGCC
ATGAGAAC) genes [24]. New STs were deposited in
the Acinetobacter MLST database (http://pubmlst.org/
abaumannii/). eBURST (version 3, http://eburst.mlst.net/)
was used to assign STs to CCs, which were defined for
those sharing identical alleles at six of seven loci. CCs were
named according to the number of the predicted founder
ST except for CC92, which has been well defined in litera-
ture. If no founder ST was predicted by eBURST, the CC
was named by the first ST assigned.
Isolates with new STs and isolate d34, of which ST
could not be determined using the pubmlst scheme,
were also subjected to MLST using the Pasteur scheme
[26]. New STs determined using the Pasteur scheme
have also been deposited into the database (http://www.
pasteur.fr/mlst/Abaumannii.html).
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